The European Commission’s latest Research and Innovation Days have placed renewed emphasis on the difficulties European companies face when attempting to turn scientific research into commercially successful technologies, highlighting the relationship between investment, regulatory conditions and international competitiveness.
The two-day event, held in Brussels on 10–11 November, brought together policymakers, researchers, investors, business representatives and technology companies to discuss Europe’s innovation capabilities.
The discussions addressed research funding, access to capital, technology development, international cooperation and the conditions required for European businesses to expand.
For companies working in technology and communications, the debate raises an important commercial question: how can Europe convert its considerable scientific expertise into businesses capable of competing internationally?
Europe’s Research Strength Does Not Guarantee Commercial Success
The European Union has an extensive network of universities, scientific institutions and research-intensive businesses.
Its research programmes support developments across artificial intelligence, biotechnology, energy, advanced manufacturing and other strategic sectors.
However, the Commission has repeatedly identified difficulties in transforming successful research into products and companies operating at international scale.
According to the European Innovation Act proposal, European innovators face obstacles involving fragmented markets, access to finance, regulatory complexity and limited commercial opportunities.
These difficulties affect the period between developing a promising technology and establishing a commercially sustainable business.
A research project may demonstrate technical feasibility without possessing sufficient capital, customer demand or management capacity to enter the market.
For start-ups, the challenge can become more acute when expansion requires hiring additional staff, establishing international operations or meeting different regulatory requirements across member states.
The European Innovation Act Seeks to Address Structural Barriers
On 9 September, the Commission proposed a European Innovation Act intended to improve conditions for innovative businesses.
The legislative proposal includes measures concerning access to public procurement, intellectual property and the commercialisation of research.
One objective is to create clearer opportunities for innovative companies to supply products and services to public-sector customers.
Government procurement can provide an important early market for technologies that have not yet achieved widespread commercial adoption.
However, smaller companies may struggle to participate in complex procurement procedures or compete against established suppliers.
The Commission wants to reduce some of these obstacles and encourage greater use of procurement to support research and development.
The Act remains a legislative proposal and has not yet established a complete new regulatory framework.
Its eventual provisions will depend on negotiations between EU institutions.
Access to Finance Remains a Central Constraint
European technology companies often face difficulties obtaining the capital required for rapid expansion.
Early-stage research funding may support product development, while later commercial growth requires substantially larger investment.
The availability of venture capital varies considerably between European countries and technology sectors.
Some businesses seek funding outside Europe or relocate important operations to markets offering greater access to investors.
The Commission’s Startup and Scaleup Strategy seeks to improve these conditions.
In August 2026, Brussels completed the legal preparations for the Scaleup Europe Fund, with a target size of €5 billion.
The initiative is intended to support companies developing strategically important technologies.
However, public investment cannot by itself resolve the structural difficulties affecting European capital markets.
The availability of private finance, institutional investors and commercially experienced management remains essential.
Intellectual Property Becomes a Commercial Asset
Another element of the innovation debate concerns intellectual property.
Research-intensive companies often possess valuable patents, software, specialised knowledge and other intangible assets.
These can represent a substantial part of a business’s commercial value.
Nevertheless, intangible assets can be difficult to use as collateral when seeking finance.
The European Innovation Act proposal addresses this problem through measures intended to improve intellectual-property valuation and financing.
Such arrangements could help businesses obtain investment without relying exclusively on conventional physical assets.
They may also encourage universities and research organisations to establish clearer arrangements for commercialising technologies developed through publicly funded projects.
For technology companies, intellectual-property strategy is therefore increasingly connected to broader decisions about investment and market expansion.
Innovation Requires Effective Market Communication
Commercialisation also depends on how businesses communicate the value of their technologies.
Scientific performance and commercial relevance are not necessarily the same.
A technically sophisticated product may struggle to attract customers if its practical benefits are not clearly demonstrated.
Companies developing advanced technologies often need to communicate simultaneously with investors, regulators, industrial customers and potential partners.
Each audience requires different information.
Investors may concentrate on market size, financial projections and competitive positioning.
Industrial customers will assess reliability, integration costs, technical compatibility and operational performance.
Regulators may require evidence concerning safety, compliance and risk management.
Clear communication cannot compensate for an uncompetitive product, but it can make a commercially viable technology easier to evaluate and adopt.
This becomes particularly important for European companies seeking to enter unfamiliar international markets.
Technology Sovereignty Depends on Industrial Capacity
The Research and Innovation Days also addressed Europe’s technological sovereignty.
This concept is often associated with reducing dependence on suppliers outside the European Union, particularly in strategically important sectors.
However, sovereignty does not necessarily require complete domestic production of every technology.
In many industries, international cooperation remains essential for access to components, expertise and markets.
The relevant question is whether European businesses and institutions retain sufficient capability to make independent commercial and strategic decisions.
That depends on investment, skilled personnel, research infrastructure, production capacity and access to international customers.
From Research Policy to Commercial Outcomes
The Commission’s innovation agenda includes several complementary initiatives, but their effectiveness will depend on implementation.
Businesses require more than additional funding announcements.
They need predictable regulatory conditions, functioning markets, access to capital and opportunities to commercialise new products.
The European Research and Innovation Days provided a forum for examining these issues.
The next test will be whether proposed reforms reduce the time and expense involved in bringing technologies to market.
For European technology companies, the practical measure of success is not simply the volume of research undertaken.
It is whether more companies can develop, finance, manufacture and sell competitive products while maintaining substantial operations within Europe.
